Strides Pharma Science Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 31 Jul 2026

Company page: Strides Pharma Science share price, financials & guidance record

Strides Pharma Science Limited reported a steady Q1 FY27 with 13% YoY topline growth, driven by strong Ex-US performance. The company maintained healthy gross and EBITDA margins despite geopolitical and inflationary pressures, while also reducing net debt. Strategic focus remains on niche US domains and expanding Ex-US markets, with key product approvals and acquisitions expected in H2.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 16.8%, net profit up 461.5% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	520	551	556	499	522 +0%	554 +1%	606 +9%	583 +17%
Expenses	464	477	488	431	460	472	531	522
EBITDA	55	74	68	67	62 +13%	81 +9%	74 +9%	61 −9%
Margin	11%	13%	12%	13%	12%	15%	12%	10%
Other income	24	2	12	2	14	103	4	78
Interest	42	34	29	30	29	27	27	29
Depreciation	21	21	22	22	22	22	25	26
Profit before tax	16	21	28	16	25 +56%	135 +543%	27 −4%	85 +431%
Tax rate	-5%	30%	43%	19%	-26%	10%	38%	14%
Net profit	17	15	16	13	32 +88%	122 +713%	16 +0%	73 +462%
EPS	1.88	1.62	1.75	1.45	3.48	13.23	1.77	7.91

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls